本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Attovia Therapeutics

22.79
+0.26001.15%
盤後22.790.00000.00%19:30 EDT
成交量:17.58萬
成交額:399.19萬
市值:10.40億
市盈率:-14.78
高:24.22
開:22.43
低:22.00
收:22.53
52周最高:28.00
52周最低:16.15
股本:4,565.13萬
流通股本:1,700.00萬
量比:0.76
換手率:1.03%
股息:- -
股息率:- -
每股收益(TTM):-1.5420
每股收益(LYR):-15.3508
淨資產收益率:--
總資產收益率:--
市淨率:-7.15
市盈率(LYR):-1.48

資料載入中...

2023/03/13

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2023/03/13

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2023/03/13

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2023/03/03

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/02

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/09/08

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/09/08

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/18

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/06/06

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/02

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/23

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2022/02/10

SEC問詢函

CORRESP [Cover] - Correspondence
2022/01/24

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/20

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/17

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/22

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/19

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/09

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/06

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2020/07/06

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership